Presented to Kiara Health for the acquisition of pharmaceutical manufacturing operations
Kiara acquired the internationally GMP compliant Novartis plant, and twenty-six marketing authorisations (MAs) from Novartis’ subsidiary generic drugs manufacturer, Sandoz South Africa, contract manufacturing selected products for Sandoz SA for a four-year period.
The local advisers to the Kiara Health deal were: ENSafrica and White & Case.
Kiara Health CEO, Dr Skhumbuzo Ngozwana thanked Ansarada, DealMakers and Exxaro for this great honour. “We thank all the partners who have supported us on this journey – White & Case, Sandoz/ Novartis, our Investors, Imperial, and FNB South Africa. We especially appreciate the 200 ex-Sandoz associates who have supported this transaction, ensuring a seamless transfer and transition to Kiara Health. We are grateful and encouraged by a deal of this nature, which is quintessentially a deal in building local capacity in a critical sector where there is an urgent need for national self-reliance – especially in the post Covid-19 era; and one that has laid the foundation and helped to bolster a successful local Pharmaceutical Manufacturing Company”, says Dr Ngozwana.